Core Viewpoint - Klotho Neurosciences has rebranded to Greenland Mines Ltd and changed its Nasdaq ticker symbol to GRML, reflecting a strategic shift towards critical minerals development in Greenland [1] Company Overview - Greenland Mines Ltd operates two divisions: Natural Resources, focusing on the Skaergaard Project in Southeast Greenland, and Cell and Gene Therapy, including the KLTO-202 indication for ALS [1] - The company holds an 80% interest in the Skaergaard Project, with an option to acquire the remaining 20% [1] Mineral Resource Details - The Skaergaard Project hosts a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 million ounces of PdEq and 23.5 million ounces of AuEq [1] - The gross undiscounted in-situ resource value is approximately $68 billion based on February 2026 metal prices [1] Strategic Communication - An investor webcast is scheduled for March 12, 2026, at 4:15 PM ET to discuss the strategic rationale behind the acquisition and its benefits for shareholders [1]

Core Viewpoint - Klotho Neurosciences Inc. has announced the acquisition of Greenland Mines Corp., which significantly enhances its resource portfolio with valuable palladium and gold deposits [1][2]. Group 1: Acquisition Details - Klotho Neurosciences will now operate under two strategic divisions: Natural Resources, focusing on the Skaergaard Project, and Cell and Gene Therapy [5]. - The acquisition will be executed through convertible preferred stock, resulting in Greenland Mines holding approximately 93% of the new entity [7]. Group 2: Resource Valuation - Greenland Mines controls an 80% interest in the Skaergaard Project, which is one of the largest undeveloped palladium, gold, and platinum deposits, valued at approximately $68 billion based on February 2026 metal prices [2][3]. - The Skaergaard Project hosts 25.4 million ounces of palladium equivalent (PdEq) and 23.5 million ounces of gold equivalent (AuEq) [3]. Group 3: Future Outlook - The company believes the current resource estimate does not fully represent the potential of the Skaergaard deposit, which remains open in all directions, with ongoing drilling campaigns yielding positive results [4]. - Klotho's leadership will remain in place post-acquisition, with the Greenland Mines leadership team joining to manage the new division [6].

Core Insights - Klotho Neurosciences has received acceptance for 18 patent claims in Australia related to the composition and use of human secreted Klotho protein (s-KL) for treating motor impairment [1] - The patent claims cover the use of a muscle-cell specific promoter linked to a nucleic acid gene sequence encoding s-KL, as well as various cellular delivery systems [1] - The CEO of Klotho emphasized the importance of these claims for expanding the company's patent estate and pursuing therapeutic options for Klotho supplementation [1] Patent Details - The accepted claims include methods for treating diseases characterized by motor impairment, such as neuromuscular diseases and specific motor neuron disorders [1] - The diseases mentioned include ALS, Charcot-Marie-Tooth disease, multiple sclerosis, and various forms of muscular dystrophy, among others [1] - The claims also encompass the use of neuronal cells and induced pluripotent stem cells (iPSC) containing the muscle-cell specific promoter and s-KL gene sequence [1] Company Overview - Klotho Neurosciences is focused on developing innovative gene and cell therapies using the s-KL protein derived from the human Klotho gene [1] - The company aims to transform the treatment of neurodegenerative disorders, including ALS, Alzheimer's disease, and Parkinson's disease [1] - Klotho's approach is positioned as a significant innovation in addressing Klotho supplementation for age-related and other neuronal pathologies [1]

Core Insights - Klotho Neurosciences, Inc. will present at the 2026 Biotech Showcase in San Francisco on January 13, 2026, at 11:30 AM PT [1] - The company focuses on developing innovative, disease-modifying cell and gene therapies targeting neurodegenerative and age-related disorders [3] Company Overview - Klotho Neurosciences, Inc. specializes in therapies derived from a patented form of the "anti-aging" human Klotho gene (s-KL) [3] - The current portfolio includes proprietary cell and gene therapy programs utilizing DNA and RNA as therapeutics, along with genomics-based diagnostic assays [3] - The management team consists of experienced individuals and advisors in biopharmaceutical product development and commercialization [3] Investor Engagement - The company will be available for one-on-one meetings with investors and potential partners during the Biotech Showcase [2]

As filed with the Securities and Exchange Commission on December 5, 2025 Registration No. 333- SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (State or other jurisdiction of incorporation or organization) Delaware 2836 86-2727441 (Primary Standard Industrial Classification Code) KLOTHO NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) (I.R.S. Employer Identification No.) 1300 South Boulevard, Suite D Charlot ...

As filed with the Securities and Exchange Commission on December 5, 2025 Registration No. 333- REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KLOTHO NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 86-2727441 (Primary Standard Industrial Classification Code) (I.R.S. Employer Identification No.) 1300 South Boulevard, Suite D Charlotte, NC 28203 Telephone: (833) 931-6330 (Address and telephone numbe ...

Revenue - The Company reported no revenue for the three months ended September 30, 2025 and 2024[114] Operating Expenses - Operating expenses decreased to $1,853,304 for the three months ended September 30, 2025, down from $2,870,932 in the same period of 2024, a reduction of approximately 35.4%[115] - For the nine months ended September 30, 2025, operating expenses increased to $5,333,124 from $3,688,584 in the same period of 2024, an increase of approximately 44.6%[118] Net Loss - The net loss for the three months ended September 30, 2025 was $2,895,585, compared to a net loss of $2,959,426 for the same period in 2024, reflecting a decrease of about 2.2%[116] - The net loss for the nine months ended September 30, 2025 was $9,222,798, compared to $4,083,109 for the same period in 2024, representing an increase of approximately 126.4%[119] Cash Flow - Net cash used in operating activities for the nine months ended September 30, 2025 was $4,610,390, compared to $2,002,358 for the same period in 2024, an increase of approximately 130.5%[121] - The Company had cash and cash equivalents of $7,348,034 as of September 30, 2025, with an accumulated deficit of approximately $19.8 million[127] - Net cash provided by financing activities for the nine months ended September 30, 2025 was $11,894,683, significantly higher than $2,173,942 for the same period in 2024[123][124] Future Outlook - The Company expects to continue incurring significant professional costs to remain publicly traded and requires additional working capital funding to execute its business plans[125][127] - The Company has no off-balance sheet arrangements as of September 30, 2025[128]

Core Insights - Klotho Neurosciences, Inc. has been awarded the Fifth Annual BioTech Breakthrough Award in the "Cell Therapy Innovation of the Year" category for its innovative gene and cell therapies targeting neurodegenerative diseases [1][2]. Company Overview - Klotho Neurosciences focuses on developing transformative therapies using a patented form of the human Klotho gene (s-KL) to treat conditions such as ALS, Alzheimer's disease, and Parkinson's disease [2][4]. - The company's therapies aim to address the underlying mechanisms of neuronal aging, potentially slowing, halting, or reversing disease progression [2]. Industry Context - The BioTech Breakthrough Awards recognize innovation in the life sciences and biotechnology sectors, highlighting excellence in biopharma, therapeutics, genomics, diagnostics, and research tools [3]. - As the global population ages, there is an increasing demand for therapies that target the root causes of age-related diseases, positioning Klotho to meet this challenge [3].

Core Insights - Klotho Neurosciences, Inc. will participate in the Longevity Biotech 2025 conference in Boston on October 22-23, 2025, focusing on advancing longevity therapeutics [1][2] - The company aims to engage in one-on-one meetings with investors and potential partners during the event to discuss collaborations and therapeutic programs [2] - Klotho specializes in developing innovative cell and gene therapies targeting neurodegenerative and age-related disorders, leveraging a patented form of the "anti-aging" human Klotho gene [3] Company Overview - Klotho Neurosciences, Inc. is a biogenetics company listed on NASDAQ (KLTO) [3] - The company focuses on disease-modifying therapies for conditions such as ALS, Alzheimer's disease, and Parkinson's disease [3] - Klotho's portfolio includes proprietary cell and gene therapy programs utilizing DNA and RNA therapeutics, along with genomics-based diagnostic assays [3]

Core Insights - Klotho Neurosciences, Inc. has allowed its Letter of Intent with Turn Biotechnologies to expire, as the proposed transaction did not align with the company's long-term strategic plan [1][2] - The company will redirect its focus and resources towards advancing its Klotho anti-aging protein research pipeline and developing treatments that promise the greatest value for patients and shareholders [2] Company Overview - Klotho Neurosciences, Inc. is a biogenetics company dedicated to developing innovative, disease-modifying cell and gene therapies utilizing a protein derived from the patented "anti-aging" human Klotho gene [4] - The company aims to transform the treatment of neurodegenerative and age-related disorders, including ALS, Alzheimer's disease, and Parkinson's disease, through its proprietary cell and gene therapy programs [4] Market Context - The longevity medicine market is one of the fastest-growing global sectors, driven by an aging population projected to reach 2.1 billion by 2050 [3] - Healthcare costs are currently at 10% of global GDP and are expected to exceed $47 trillion by 2030, highlighting the significant opportunity in the longevity sector [3]